Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Clinical and histopathological predictors of outcome in malignant meningioma

Research output: Contribution to journalJournal articleResearchpeer-review

  1. WHO grade I meningiomas: classification-tree for prognostic factors of survival

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Skull base versus non-skull base meningioma surgery in the elderly

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Meningiomas: skull base versus non-skull base

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Living with the cerebellar mutism syndrome: long-term challenges of the diagnosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Introduction to the cerebellar mutism syndrome

    Research output: Contribution to journalComment/debateResearchpeer-review

  3. The supplementary motor area syndrome and the cerebellar mutism syndrome: a pathoanatomical relationship?

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Laser Ablation of Abnormal Neurological Tissue Using Robotic Neuroblate System (LAANTERN): Procedural Safety and Hospitalization

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

We investigated possible clinical and histopathological prognostic factors in a malignant meningioma cohort with comprehensive long-term population-based follow-up data. Twenty-four consecutive patients treated surgically for malignant meningioma at the Department of Neurosurgery and the Department of Pathology, Rigshospitalet, Copenhagen, Denmark, from December 2000 to March 2014 were retrospectively evaluated regarding progression-free survival (PFS) and overall survival (OS). Clinical parameters were recorded. All specimens underwent immunohistochemical analysis for Ki-67 and phosphohistone-H3 (PHH3). Prognostication was assessed with Cox proportional hazard regression analysis. The median follow-up was 46.1 months (range 0.7-150.7). The median progression-free survival was 16.5 months (95% CI 11.4-43.0) and the median overall survival was 46.6 months (95% CI 20.4-NA). Six patients were alive at the end of follow-up; two of these had not experienced a recurrence. No clinical parameter showed significant association with PFS or OS. Mitotic index (MI) was significantly associated with PFS and OS, and PHH3 MI with PFS. Immunohistochemical reactivity of Ki-67 > 10% was a negative predictor of PFS (HR 3.92, 95% CI 1.47-10.4, p = 0.0063) and OS (HR 3.35, 95% CI 1.12-10.1, p = 0.0313). The histological subgrouping of grade III meningioma into anaplastic and non-anaplastic revealed increased PFS for the latter (HR 4.57, CI 95% 1.32-15.7, p = 0.0164). We could not verify previous clinical parameters as prognostic factors in malignant meningioma. MI and the PHH3 MI were prognostic within WHO grade III meningiomas for PFS. An overall tumor staining of Ki-67 > 10% correlated with PFS and OS within grade III tumors.

Original languageEnglish
JournalJournal of Neurosurgery
Volume43
Issue number2
Pages (from-to)643-653
Number of pages11
ISSN0022-3085
DOIs
Publication statusPublished - Apr 2020

    Research areas

  • Ki-67, Malignant meningioma, Phosphohistone-H3, Prognostic factors

ID: 58349149